New vaccine aims to train immune system against HPV cancers

NCT ID NCT06319963

Recruiting now Disease control Sponsor: Theravectys S.A. Source: ClinicalTrials.gov ↗

First seen Nov 06, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This early-stage trial tests a new vaccine (Lenti-HPV-07) designed to help the immune system fight HPV-related throat and cervical cancers. About 72 adults with either advanced or newly diagnosed cancer will receive the vaccine. Researchers will monitor safety and whether the vaccine triggers a strong immune response against the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Florida Cancer Specialists (from Sarah Canon research Institute)
RECRUITING

Orlando, Florida, 32827, United States

Contact
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

Contact
Oklahoma Cancer Specialists and Research Institute, LLC
RECRUITING

Tulsa, Oklahoma, 74146, United States

Contact
Tampa General Hospital
RECRUITING

Tampa, Florida, 33606, United States

Contact

Conditions

Explore the condition pages connected to this study.

HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA HPV-RELATED CERVICAL CARCINOMA